ABSTRACT
Background: Polycystic Ovary Syndrome [PCOS] is presented with characteristic complications such as chronic an ovulation, obesity, and hyperandrogenism which can affect sexual function in women of reproductive age
Objective: Herein we evaluated the frequency and predisposing factors of sexual dysfunction in infertile PCOS patients
Materials and Methods: In this cross-sectional study, 130 married women with a definite diagnosis of PCOS who were referred due to infertility were recruited. They were evaluated concerning their sexual function in the domains of desire, arousal, lubrication, orgasm, satisfaction and pain with the female sexual function index [FSFI] questionnaire
Results: The frequency of sexual dysfunction was verified 57.7% in PCOS patients with the domains of desire and arousal being commonly affected in 99.2% and 98.5%of cases respectively. BMI had a significant effect on sexual desire and arousal [p=0.02] while the effect of hirsutism was significant on all domains [p<0.001 for total FSFI score] except for dyspareunia
Conclusion: PCOS patients markedly suffer from sexual dysfunction as comorbidity. It seems appropriate to screen all PCOS patients for sexual function with a simple short questionnaire such as FSFI. Targeted interventions could be considered to help improve their quality of life along with other treatments
ABSTRACT
General concern is that the pregnancy rate is higher with GnRH-agonist as a protocol of pituitary suppression. GnRH-antagonist protocol provides a shorter period of administration and an easy flexible protocol. In this study, the outcomes of GnRH agonist and antagonist in ICSI cycles are compared in normo responder patients. In this randomized clinical trial, 300 normoresponders undergoing ICSI were randomly divided to GnRh agonist [n=150] and GnRh antagonist [n=150] groups. The main outcome measurements were chemical, clinical and ongoing pregnancy rates [PR]. The mean duration of stimulation were 9.6 +/- 1.6 and 8.2 +/- 1.6 days in agonist and antagonist groups respectively [p=0.001]. The mean number of MII oocyte retrieved in agonist and antagonist groups were 7.7 +/- 4.0 and 6.9 +/- 4.3 respectively [p=0.03]. There was no significant difference between two groups regarding mean number of gonadotrophin ampoules, follicles, occytes, total embryos and good quality embryos, OHSS incidence, and abortion rate. Chemical pregnancy rate was 35.3% in agonist and 39.3% in antagonist group. Clinical pregnancy rate was 35.3% in agonist and 34% in antagonist group. Ongoing pregnancy rate was 45 [31.3%] in agonist and 44 [29.3%] in antagonist group. There was no significant difference between two groups in pregnancy rates. In this study antagonist protocol was shown to be an easy, safe and friendly protocol in Iranian normoresponder patients, having similar outcomes with standard agonist protocol but shorter period of stimulation